Saturday 17 October 2026
Export MESO’s income statement to Excel — free account
Mesoblast Limited
MESO Healthcare Biotechnology
Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025. Insiders bought in the last twelve months.
13.28
0.67
−4.80%
Follow MESO
| Older periods | Jun '23 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
81.08 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(37.36) | — | — | — | |
P/B ratio |
1.21 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
86.07 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(10.20) | — | — | — | |
EV/FCF |
(10.15) | — | — | — | |
Quick Ratio |
1.87 | 2.60 | 0.56 | 1.35 | |
Current Ratio |
1.95 | 2.71 | 0.96 | 1.58 | |
Net Debt/EBITDA |
(2.26) | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
16.25% | 17.27% | 18.21% | 16.22% | |
Debt/Equity |
0.22 | 0.23 | 0.26 | 0.22 | |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.04) | 0.00 | (0.05) | (0.11) | |
Interest Coverage |
(3.93) | — | — | — | |
Research and Development Expense of Revenue |
347.84% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
295.22% | — | — | — | |
Intangible Assets out of Total Assets |
0.86 | 0.86 | 0.88 | 0.73 | |
Share Based Compensation of Revenue |
57.51% | — | 0.00% | 0.00% | |
Graham Net Nets |
(0.14) | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(14.32%) | — | — | — | |
Free Cash Flow Yield |
(10.45%) | — | — | — | |
Revenue per Share |
0.02 | — | — | — | |
Operating CF per Share |
(0.21) | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.92 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
6.45 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.45 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(16.31) | (0.20) | (20.76) | (30.83) | |
Working Capital |
39.68 | 53.79 | (3.07) | 74.41 | |
Capital Expenditures |
(0.04) | (0.20) | (0.11) | (0.48) | |
Net Current Asset Value |
(85.92) | (76.40) | (122.38) | (5.14) | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
5.70 | 3.93 | 4.06 | 25.85 | |
Average Payables |
21.61 | 14.21 | 17.43 | 27.27 | |
Average Assets |
665.78 | 677.39 | 660.69 | 716.37 | |
Average Common Equity |
499.44 | 515.77 | 480.63 | 528.43 |
Columns are period end dates